Codexis (NASDAQ:CDXS) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Other equities analysts have also issued reports about the stock. HC Wainwright set a $8.00 price objective on shares of Codexis and gave the company a “buy” rating in a report on Friday, August 11th. Jefferies Group reissued a “buy” rating and set a $9.00 price objective (up from $8.00) on shares of Codexis in a report on Monday, October 2nd. Zacks Investment Research raised shares of Codexis from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, ValuEngine raised shares of Codexis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $7.50.

Shares of Codexis (NASDAQ CDXS) traded up $0.02 during mid-day trading on Friday, reaching $6.93. 252,679 shares of the company traded hands, compared to its average volume of 194,505. Codexis has a 12 month low of $3.60 and a 12 month high of $7.95.

In related news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of Codexis stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $5.78, for a total transaction of $6,126,800.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 9.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Royce & Associates LP purchased a new position in Codexis in the third quarter worth $1,089,000. Telemark Asset Management LLC purchased a new position in Codexis in the third quarter worth $13,633,000. Wells Fargo & Company MN grew its holdings in Codexis by 227.6% in the third quarter. Wells Fargo & Company MN now owns 390,797 shares of the biotechnology company’s stock worth $2,599,000 after purchasing an additional 271,503 shares during the last quarter. Baillie Gifford & Co. grew its holdings in Codexis by 1.1% in the third quarter. Baillie Gifford & Co. now owns 1,478,097 shares of the biotechnology company’s stock worth $9,830,000 after purchasing an additional 16,684 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in Codexis by 7.4% in the second quarter. California State Teachers Retirement System now owns 72,298 shares of the biotechnology company’s stock worth $394,000 after purchasing an additional 5,000 shares during the last quarter. 65.71% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Codexis (CDXS) Rating Increased to Hold at BidaskClub” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/codexis-cdxs-rating-increased-to-hold-at-bidaskclub/1739379.html.

About Codexis

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.